Core Viewpoint - North China Pharmaceutical (600812.SH) has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating the product meets the basic entry requirements for centralized procurement and has equivalent efficacy to the original product [1] Group 1 - The injectable vancomycin hydrochloride is effective against infections caused by methicillin-resistant Staphylococcus aureus and other bacteria, including conditions such as sepsis, infective endocarditis, osteomyelitis, arthritis, burns, surgical wound infections, pneumonia, lung abscess, empyema, peritonitis, and meningitis [1] - The product can also be administered orally for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and staphylococcal enterocolitis [1] - The approval of this product enhances the company's product structure in the field of anti-infection, building on its existing product, Vanxun (injectable desacetyl vancomycin) [1]

Core Viewpoint - North China Pharmaceutical has received approval from the National Medical Products Administration for the injection of Vancomycin Hydrochloride (0.5g), with a validity period until August 25, 2030 [1] Group 1: Product Information - Vancomycin Hydrochloride primarily exerts its bactericidal effect by inhibiting the biosynthesis of the bacterial cell wall [1] - The drug can alter the permeability of bacterial cell membranes and RNA synthesis [1] - It is suitable for intravenous infusion for infections caused by Methicillin-resistant Staphylococcus aureus and other bacteria, and can be taken orally for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile, as well as Staphylococcal enterocolitis [1]

Core Viewpoint - North China Pharmaceutical (600812.SH) has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating the product meets the basic entry requirements for centralized procurement and has equivalent efficacy to the original product [1] Group 1: Product Information - Injectable vancomycin hydrochloride primarily acts by inhibiting bacterial cell wall biosynthesis and can alter bacterial cell membrane permeability and RNA synthesis [1] - The intravenous administration is suitable for infections caused by methicillin-resistant Staphylococcus aureus and other bacteria, including conditions such as sepsis, infective endocarditis, osteomyelitis, arthritis, burns, surgical wound infections, pneumonia, lung abscess, empyema, peritonitis, and meningitis [1] - The oral form is indicated for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and staphylococcal enterocolitis [1] Group 2: Market Position and Strategy - The approval of injectable vancomycin hydrochloride enhances the company's product portfolio in the anti-infection field, building on its existing product, Vanxun (injectable deacetyl vancomycin hydrochloride) [1] - This development is expected to effectively improve the company's competitive position in the market for anti-infection products [1]

Core Viewpoint - North China Pharmaceutical (600812) has received approval from the National Medical Products Administration for the injection of Vancomycin Hydrochloride (0.5g), indicating successful completion of the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - The approved Vancomycin Hydrochloride is primarily used to inhibit bacterial cell wall biosynthesis, demonstrating bactericidal activity [1] - Vancomycin also alters the permeability of bacterial cell membranes and RNA synthesis, making it effective against infections caused by Methicillin-resistant Staphylococcus aureus and other bacteria [1]

Core Viewpoint - The company has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating that the product meets the basic requirements for centralized procurement bidding and has therapeutic effects equivalent to the original product [1] Group 1 - The approval of injectable vancomycin hydrochloride (0.5g) enhances the company's product portfolio in the anti-infection field [1] - The new product complements the existing product, vancomycin (injection of vancomycin hydrochloride), thereby improving the company's offerings in the market [1]